Speech-Language Pathologists in Averill Park, NY Accepting Medicare
6 Speech-Language Pathologists found. Showing 1 - 6
 Mrs. Catherine C. Davis Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8439 Miller Hill Rd, Averill Park, NY 12018 Phone: 518-674-7075 |
Mrs. Jaclyn Daloia, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 146 Gettle Rd, Averill Park, NY 12018 Phone: 518-674-7068 |
Jessica Pelizari Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2398 Ny Highway 43, Averill Park, NY 12018 Phone: 215-954-9074 |
Mrs. Kerry Gully, MS, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 333 Ny 351, Averill Park, NY 12018 Phone: 518-674-7100 |
Mrs. Brenda J Westbrook, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 146 Gettle Rd, Averill Park, NY 12018 Phone: 518-674-7068 |
Christine A Harrington Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14 Fiddlers Ln, Averill Park, NY 12018 Phone: 518-330-5262 |
News Archive
Ticagrelor therapy, without aspirin, can benefit patients with acute coronary syndrome
Patients with acute coronary syndrome (ACS) who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for nine months had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.
Protalix Biotherapeutics reports completion of its Phase III trial of prGCD
Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company's proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, Israel and South Africa. No serious adverse events were reported in this trial.
Immunity to dengue can protect against Zika infection, study shows
In the epicenter of the Zika epidemic in northeast Brazil, 73 percent of people living in an urban slum in Salvador were infected in 2015. However, in this highly affected population, those with immunity to dengue, a genetically similar virus, had a reduced risk of infection with Zika.
Brain research funds crisis: Report
According to the European College of Neuropsychopharmacology there is a dramatic drop in private and public funding for research in brain diseases that has led to a "withdrawal of hope" for millions of sufferers and could delay the search for treatments and cures by 30 years.
› Verified 8 days ago
Speech-Language Pathologists
Chiropractors
Physical Therapists